Dermoscopic assessment of long‐term systemic therapy with dupilumab in adult atopic dermatitis

Author(s):  
M. Ferrillo ◽  
C. Patruno ◽  
A. Villani ◽  
M. Scalvenzi ◽  
G. Fabbrocini ◽  
...  
2019 ◽  
Vol 47 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Hidemi Nakagawa ◽  
Osamu Nemoto ◽  
Atsuyuki Igarashi ◽  
Hidehisa Saeki ◽  
Ryusei Murata ◽  
...  

Membranes ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 26
Author(s):  
Sara Metwally ◽  
Daniel P. Ura ◽  
Zuzanna J. Krysiak ◽  
Łukasz Kaniuk ◽  
Piotr K. Szewczyk ◽  
...  

Atopic dermatitis (AD) is a chronic, inflammatory skin condition, caused by wide genetic, environmental, or immunologic factors. AD is very common in children but can occur at any age. The lack of long-term treatments forces the development of new strategies for skin regeneration. Polycaprolactone (PCL) is a well-developed, tissue-compatible biomaterial showing also good mechanical properties. In our study, we designed the electrospun PCL patches with controlled architecture and topography for long-term release in time. Hemp oil shows anti-inflammatory and antibacterial properties, increasing also the skin moisture without clogging the pores. It can be used as an alternative cure for patients that do not respond to traditional treatments. In the study, we tested the mechanical properties of PCL fibers, and the hemp oil spreading together with the release in time measured on skin model and human skin. The PCL membranes are suitable material as patches or bandages, characterized by good mechanical properties and high permeability. Importantly, PCL patches showed release of hemp oil up to 55% within 6 h, increasing also the skin moisture up to 25%. Our results confirmed that electrospun PCL patches are great material as oil carriers indicating a high potential to be used as skin patches for AD skin treatment.


2021 ◽  
Vol 69 (4) ◽  
pp. 888-892
Author(s):  
Joseph I Clark ◽  
Brendan Curti ◽  
Elizabeth J Davis ◽  
Howard Kaufman ◽  
Asim Amin ◽  
...  

High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease control have also demonstrated improved survival compared with patients who progress, but limited data are available describing the long-term course. The aim of this study was to better characterize long-term survival following successful HD IL-2 treatment in patients with no subsequent systemic therapy. Eleven HD IL-2 treatment centers identified patients with survival ≥5 years after HD IL-2, with no subsequent systemic therapy. Survival was evaluated from the date of IL-2 treatment to June 2017. Treatment courses consisted of 2 1-week cycles of HD IL-2. Patients were treated with HD IL-2 alone, or HD IL-2 followed by local therapy to achieve maximal response. 100 patients are reported: 54 patients with mM and 46 patients with mRCC. Progression-free survival (PFS) after HD IL-2 ranges from 5+ years to 30+ years, with a median follow-up of 10+ years. 27 mRCC and 32 mM are alive ≥10 years after IL-2. Thus, a small subset of patients with mM and mRCC achieve long-term PFS (≥5 years) after treatment with HD IL-2 as their only systemic therapy. The ability of HD IL-2 therapy to induce prolonged PFS should be a major consideration in studies of new immunotherapy combinations for mM and mRCC.


Author(s):  
Stine Elsgaard ◽  
Anne Kathrine Danielsen ◽  
Jacob P. Thyssen ◽  
Mette Deleuran ◽  
Christian Vestergaard

2020 ◽  
Author(s):  
Baidurjya Bhattacharjee ◽  
Vanlalfakawmi Pachuau

AbstractAtopic dermatitis (AD) is a common dermatological disorder in children, which is chronic and of a relapsing nature. It is very common in children, with a fair chance of lifetime prevalence of the disease. The following case is of a child 5 months of age who was suffering from AD since 2 months of age. After the first prescription, complaints were much improved. Following that, the child was treated with complex homoeopathic medicines by another physician, which aggravated the condition. Following stoppage of medicines due to an aggravation, a second remedy was thereafter prescribed that provided long-term relief to the patient.


Sign in / Sign up

Export Citation Format

Share Document